$11.48
+0.31 (+2.78%)
Open$11.11
Previous Close$11.17
Day High$11.63
Day Low$11.01
52W High$19.15
52W Low$3.92
Volume—
Avg Volume93.0K
Market Cap92.08M
P/E Ratio—
EPS$-0.86
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
-38.7% upside
Current
$11.48
$11.48
Target
$7.04
$7.04
$5.84
$7.04 avg
$9.41
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 83.20M | 67.18M | 4.60M |
| Net Income | 22.52M | 16.36M | -132,709 |
| Profit Margin | 27.1% | 25.7% | -2.9% |
| EBITDA | 26.16M | 20.07M | -214,542 |
| Free Cash Flow | — | — | -85,981 |
| Rev Growth | +23.9% | +23.9% | -8.7% |
| Debt/Equity | 0.04 | 0.04 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |